Category Archives: Business of Medicine

Alternative medicine, Biotech, Business of Medicine, Clinics, Consultations, Doctors, Drugs, Genetics, Gynecology, Health 2.0, Health Reform, Healthcare, Healthcare Information, Healthcare Professionals, Healthcare Services, Medicine, Online, Society

New Website Dedicated To Stem Cell Investors

Leave a comment

Investor Stem Cell (http://www.investorstemcell.com) is dedicated to bringing investors and stakeholders together in thoughtful discussion to educate and publicize the incredible medical advancements taking place in the regenerative medicine sector. Scientists are using stem cells both (hESC) and (iPSC) in hopes of easing the suffering of hundreds of millions of people world wide.

Our society is on the verge of a quantum leap moment in time thanks to regenerative medicine.

Regenerative medicine and Stem Cell research:

Utter those words at your next dinner party or casual gathering of friends and family. You will receive a concoction of half-truth’s and out right fallacy responses. Stem Cell research conjures images of futuristic Star–Trek like preservation chambers, human looking ears protruding oddly from the backs of mice, or worse yet an image of a late term fetus. Nothing could be farther from the truth when entering the reality of Regenerative medicine.

Never before has this area of research been more exciting and promising than right now. There is a medical revolution brewing, and like any revolution, there are those who want to suppress this uprising for continued personal and ideological gains. If we were to take all the major advances in the past 500 years of human medical history and multiply its effect by 10 fold it still would not compare to the paradigm shift in health care delivery that the world may witness in this decade using stem cells. Imagine that an $800,000 heart transplant is no longer needed and that instead the same money spent on one patient can now be stretched out to treat 20 patients who are needing a heart transplant. Is this what Regenerative medicine has in the offing? Only time will tell. Our healthcare system could very well be on the verge of a quantum leap moment thanks to regenerative medicine.

The Food and Drug Administration (FDA) authorized 3 trials using human embryonic stem cells (hESC) in late 2010. Validation of hESC research efforts and the culmination of billions spent on research are coming to fruition. FDA validation for the treatments of spinal cord injury and age related macular degeneration is expected in 2011. It may be the shot heard around the world event sometime in late Q-4 2011 for the Regenerative medicine sector.

Via EPR Network
More Healthcare press releases

Business of Medicine, Doctors, Healthcare, Healthcare Products, Healthcare Professionals, Healthcare Services, Hospitals, Medical Apparel, Medicine, Nurses

Medelita medical coats feature state of the art fabrics and durable design features

Leave a comment

Medelita®, maker of breakthrough performance medical coats for both men and women, offers the best selection for those medical professionals who are looking for functional, professional appearing coats. Featuring state of the art materials and smart, flattering designs, Medelita continues to push above and beyond the competition in order to offer medical professionals the very best quality and selection in the medical uniform market.

Medelita medical coats are made from pre-shrunk, 100% cotton textured fabric, which allow for a soft, sophisticated finish that is immediately noticeable. While most medical coats are unisex in styling, Medelita coats are contoured gender specifically for men and women, creating a durable and functional fitting garment that remains comfortable throughout the work day. The overall dimensions and styling of the medical coats are specifically designed to allow for ample forward reach without limiting range of motion in the arms, shoulders, or neck. In addition, Medelita coats also offer modern features like women’s rounded lapels and men’s blazer chest pockets.

As medical professionals wear medical coats in high pressure, stressful situations, Medelita medical coats use breathable 100% cotton fabric that features High-IQ Easy Care Plus wrinkle resistance and Advanced Dual Action Teflon fabric stain protector, the latter of which allows fluids to simply run right off the fabric.

Via EPR Network
More Healthcare press releases

Business of Medicine, Doctors, Healthcare, Healthcare Products, Healthcare Professionals, Healthcare Services, Hospitals, Medical Apparel, Medicine, Nurses

Medelita partners with the Society for Dermatology Physician Assistants

Leave a comment

Medelita®, maker of breakthrough performance lab coats for both men and women, announces a new partnership with the Society of Dermatology Physician Assistants. Member benefit discount and affiliation agreement begin on May 1st.

The Society of Dermatology Physician Assistants is a non-profit professional organization comprised of individuals who provide dermatologic care, or have expressed interest in the field of dermatology. The SDPA organization, founded in 1994, has over 1,700 members and continues to grow. The main focus of the organization is to provide continuing medical education to its members, form leadership structure, act as an advocate for members, and develop resources for the evaluation and hiring of Physician Assistants. Medelita is proud to have this affiliation with such a prestigious PA organization, as the founder is also a PA. The partnership is extremely complimentary.

Dermatology PAs find Medelita lab coats to be especially professional and classy, with a comfortable, ergonomic fit. With a fit similar to professional clothing, and styling and workmanship improvements throughout, doing procedures from multiple angles and positions is now easier and more comfortable. Coupled with the Advanced Dual Action Teflon® fabric protector, the performance of the lab coats is ideal for those clinicians who are at higher risk for exposure to bodily fluids or other spills. Medelita high-performance lab coats help to ensure a clean, bright white appearance by preventing soil and stains from setting in, and also allowing a fluid barrier.  They wash better than any other lab coat available, and stay bright white.

“We recently received a testimonial from a dermatology PA who said that on the very first day that she received her Medelita lab coat, blood splashed onto the sleeve during a procedure,” shares Lara Manchik, PA-C and founder. “She simply “brushed” it off with a hand towel – with no trace of it left on the surface.  Her supervising MD immediately asked where he could get a similar coat of the same performance quality.”

Via EPR Network
More Healthcare press releases

Business of Medicine, Doctors, Healthcare, Healthcare Products, Healthcare Professionals, Healthcare Services, Hospitals, Medical Apparel, Medicine, Nurses

Medelita Gives Back With Newest Affiliation

Leave a comment

Medelita®, lab coat manufacturer and online retailer upscale men’s and women’s medical apparel, is pleased to announce their latest affiliation with the American Academy of Cosmetic Dentistry. Currently AACD members who make purchases through Medelita.com receive a 10% discount. In addition to this member discount, the premier lab coat and medical scrubs retailer will donate 5% off every purchase to the Give Back a Smile Program.

The AACD is dedicated to advancing excellence in cosmetic dentistry and encouraging high standards in patient care. The American Academy of Cosmetic Dentistry Charitable Foundation’s (AACDCF) mission is to assist in rebuilding the lives and dignity of survivors of domestic violence through compassionate cosmetic dental services and support programs. Our program provides restorative and cosmetic dentistry in the smile zone at no cost to qualified survivors through our nationwide network of volunteer cosmetic dentists and our support team of laboratories and dental manufacturers. Similarly, Medelita also holds elevated standards in providing professional, sophisticated, technically advanced apparel to the dentists, physicians, and surgeons they serve. Thus, the affiliation is a synergistic fit.

AACD members are able to choose from four dental-specific lab coats, or from seven additional lab coats and multiple colors of men’s and women’s scrubs, all visible at www.medelita.com. In addition to lab coats and scrubs, Medelita offers the very best clogs available to healthcare professionals. Medelita not only provides the essentials, but specifically designs dental-specific lab coats with cuffed sleeves and optional closure to the neck. By following OSHA recommendations for garment construction, and combining those features with quality construction and Advanced Dual Action Teflon® performance fabric, members appreciate Medelita as a thoughtful uniform ideal for dentists.

Members of the AACD will receive a 10% discount on all purchases made through Medelita by entering the promotional code GBSMILE. In addition, with every purchase made, Medelita will donate 5% to the Give Back a Smile Program. This program founded by the AACD was developed in recongnition of addressing the needs in the communities of AACD members. Volunteer cosmetic dentists and laboratory technicians agree to restore the broken and damaged teeth of survivors of intimate partner violence at no cost. More than 1,000 U.S applicants have received services from this program.

Via EPR Network
More Healthcare press releases

Business of Medicine, Doctors, Healthcare, Healthcare Products, Healthcare Professionals, Healthcare Services, Hospitals, Medical Apparel, Medicine, Nurses

Medelita Providing In-House Embroidery Services

Leave a comment

Medelita®, breakthrough performance maker in medical scrubs and lab coats for both men and women, announces that all embroidery services are now completed in-house. With two top-of-the-line embroidery machines and an expert embroidery team, the premier medical apparel retailer is able to provide high quality customization without the need to outsource.

Medelita, known for their superior quality physician scrubs and performance lab coats has always offered custom embroidery services for their clients. Previously outsourced, resulting in lengthy lead times and frustrating delays, customers can now opt for Medelita in-house customization options and experience less than 10 day completion on any lab coat or medical scrub top embroidery order. Embroidery is completed by artisans with complex digitization experience, resulting in the very best quality logo and name & title stitching in the medical apparel industry. Custom options include name & title embroidery up to 3 lines, professional organization logo embroidery, and custom logo design for private practices, hospitals or university settings.

The fine quality and careful precision that goes into every stitch is consistent with the high standards that Medelita maintains on their lab coats and scrubs. Founder Lara Manchik, PA-C, states “Embroidery is the closest thing to wearing your diploma. For that reason it must be perfectly displayed, as a symbol of prestige and aptitude.”

With lab coat embroidery prominently displayed as acknowledgement of one’s educational achievements, physicians and surgeons can feel distinguished and elegant with professional embroidery from Medelita.

By conducting all embroidery services in-house, Medelita can ensure that the finished product is met to their high standards. All embroidered items go through a triple-check process that boasts an error rate of less than 0.01%. No other medical apparel company performs all these types of services strictly in-house, nor with such high standards or resultant quality.

Via EPR Network
More Healthcare press releases

Business of Medicine, Cosmetic Dentistry, Health Reform, Healthcare, Healthcare Professionals, Healthcare Services, Medicine, Optometry, Public Health, Society, Veterinarians

Housing Market Crash and Rising Medical Costs, Is There A Connection?

Leave a comment

As millions of American homeowners know, the housing market crash was fueled by inflated home values and bank loans that were high above the equity or actual value of “underwater” homes. According to Trisha Lotzer, JD., health-care attorney and CEO of Physis, Inc., a similar threat for banks, borrowers and owners of many of the nation’s medical, dental, optometry and veterinary practices must be averted.

Like residential real estate, medical practices may be marketed and sold by brokers. Brokers in the business of selling medical practices commonly charge 7-12% commission. The commission alone can add $80,000 to $2,000,000 to the purchase price, depending on the size of the facility–and drive up the bank note accordingly.

Like real estate agents, the job of the practice broker is to get the seller the highest selling price possible. Unlike real estate agents, however, brokers are often the only ones who value the practices they have for sale–giving them a built in incentive to inflate the value of practices and increase their commission. Ross Landreth, MBA, explains that the problem occurs when a practice is arbitrarily valued, purchased and financed at $1,500,000, but only has an actual fair market value (per USPAP approved valuation standards) of $850,000. This could mean that the practice does not cash-flow at $1,500,00 and that the new purchasers would have to raise the price of services in order to maintain profitability and pay back the bank note. This increase in the cost of health care does not increase the earnings of the practice owners or physicians but is passed along to patients and insurance providers.

Via EPR Network
More Healthcare press releases

Biotech, Business of Medicine, Diseases, Drugs, Healthcare, Healthcare Information, Healthcare Professionals, Healthcare Solutions, Medicine, Online, Pharmaceuticals, Society

Medical Innovation Protection Stressed in EU-India Free Trade Agreement Talks

Leave a comment

The Financial Express published an article on the Free Trade Agreement (FTA) talks that continue between the European Union (EU) and India. One of the most discussed and disagreed upon parts of the proposed FTA involves the need for protecting the intellectual property of pharmaceutical companies in order to promote medical innovation and investment in the development of new medicines and research. This disagreement about whether data exclusivity in the pharmaceutical sector should be included has resulted in the delay of finalizing the FTA.

Pharmaceutical companies rely on data exclusivity to protect the investment made in developing the medication that is used throughout the world. Millions of dollars are spent on clinical trials to prove the safety and effectiveness of these drugs. These exclusive rights prevent competitors from obtaining marketing licenses for lower cost versions of these drugs.

Global Health Progress (GHP) is committed to being part of the effort to create a sustainable health care system that includes improving access to health care and continuing medical innovation and progress for all people. While the pharma industry is divided on the issue, GHP supports efforts to improve regulations protecting pharmaceutical companies’ intellectual property. Without this protection, the funding of studies that bring these medications to market could suffer.

Improving health care systems and access to medicines, especially in the developing world, requires multifaceted approaches and solutions. Research-based biopharmaceutical companies are active partners in some of the largest and boldest health initiatives that explore new and effective ways to provide treatment, care and education to millions of people in developing countries.

About Global Health Progress:
Global Health Progress also supports efforts to raise awareness and mobilize resources to address health challenges in the developing world by bringing local leaders together with international health experts, policymakers, donor governments, and the private sector.

www.globalhealthprogress.org;

twitter.com/globalhealth;

facebook.com/pages/Global-Health-Progress/124850684219049;

linkedin.com/groups?home=&gid=2972068

Via EPR Network
More Healthcare press releases

Biotech, Business of Medicine, Diseases, Drugs, Healthcare, Healthcare Information, Healthcare Professionals, Healthcare Solutions, Medicine, Online, Pharmaceuticals, Society

Global Health Progress Amplifies Report Calling for Funding Products to Fight Neglected Tropical Diseases

Leave a comment

The third-annual Global Funding of Innovation for Neglected Diseases (G-FINDER) survey was released last week revealing both good and bad news for the funding of neglected diseases in the developing world. In a press release issued by Policy Cures, an independent group providing research and analysis for those involved in the creation of new pharmaceuticals for neglected diseases, the group reveals that while funding for neglected diseases has increased, funding for new products has decreased.

Funders appear to be focusing more of their money toward traditional basic research. This shift has caused a $50 million drop in funding for Product Development Partnerships (PDP), non-profit organizations that partner with external organizations to drive product development for neglected diseases, including neglected tropical diseases.

Report author Dr Mary Moran, Director of Policy Cures warns funders not to “take their eyes off the ball” in the press release, stating that while the increase in funding is encouraging it is important that the funds are spent wisely.

Global Health Progress has worked with partner groups to encourage and sustain funding for the research and development of new products. The innovative research and development (R&D) of new drugs and vaccines is a critical component of improving health care and combating epidemics of neglected tropical diseases in developing countries. There are no vaccines or cures for some widespread and life threatening diseases such as malaria, while existing treatments for diseases such as tuberculosis are becoming less effective due to drug resistance.

Read the full press release from Policy Cures here:
http://globalhealthprogress.org/mediacenter/wp-content/uploads/G-FINDER_Year_3_media_release.pdf,
or read the G-FINDER report on the Policy Cures website:
http://www.policycures.org/downloads/g-finder_2010.pdf.

Via EPR Network
More Healthcare press releases

Business of Medicine, Health Products, Healthcare, Healthcare Information, Healthcare Products, Healthcare Professionals, Medicine, Online, Pharmaceuticals

Big Mountain Pharmacy Launches a New Blog: Blogging the Drugs

Leave a comment

One thing that has often been lacking from online Canadian pharmacies is information. Not only about the drugs on sale themselves, but also about illnesses and general news on the medical industry such as regulation and equipment.

That is what triggered Big Mountain Drugs to start their health information blog, which is now fully up and running on their website offering articles packed with information about common illnesses such as Alzheimer’s, erectile dysfunction (impotence) and acne. Not only that, they have also released articles giving useful information to help with particularly common issues. These include helping patients with poor eyesight by giving tips on how to identify medication safely, and giving family and friends of patients’ advice on how to tell the difference between dementia and depression.

Information like this is extremely valuable to patients, as they can learn more about the drugs that they are taking and the conditions that they are taking them for. The knowledge to patients increases safety as they can easily spot the symptoms of complex or potentially dangerous illnesses, and learn how to deal with the issues that come with many conditions. Blogging the Drugs from Big Mountain pharmacy, which can be found on their website, now lists many informative articles to help their customers. All of the information is free, and is written by medical professionals giving accurate and interesting information and facts.

One customer said: “Blogging the Drugs from Big Mountain pharmacy is extremely helpful and I’ve discovered a lot of new things about my illness that I didn’t know before, including information about the drugs that I am taking so that I can keep an eye out for side effects. It makes me feel much safer that I have more knowledge than I did before”.

Big Mountain Drugs commented “We wanted to add value to our customers by allowing them to make more informed decisions. Although they cannot buy most of the drugs without a prescription, it still gives them the opportunity to learn about the drugs that they are prescribed by their doctor so that they can speak with their doctor if they have any concerns. It also helps them to learn about their illnesses so that they can be aware of any issues such as symptoms of their conditions”.

One concern however, is that online Canadian pharmacies as of recent times, are no longer allowed to advertise on Google unless it is in their own country, which will mean that many people searching for information on drugs online will not be able to find the blog unless they live in Canada if they use Google to search for it.

You can join the blog on Facebook (bigmountaindrugs) and Twitter (bigmountaindrug), some of the most popular social networking sites so it is always very easy to connect and check out any new information that is issued by Big Mountain Drugs. They also post videos on Youtube and you can subscribe by RSS feed so that you get information in new articles as soon as they are posted online.

Via EPR Network
More Healthcare press releases

Biotech, Business of Medicine, Diseases, Drugs, Healthcare, Healthcare Information, Healthcare Professionals, Healthcare Solutions, Medicine, Online, Pharmaceuticals, Society

Global Health Progress Encourages Global Partnerships on Access to Health Care

Leave a comment

Starting this month, members of Congress will be looking closely at U.S. spending as they work with the White House to build the 2012 budget. One area that has come under increased scrutiny is U.S. spending on global health programs. Several groups last week announced a petition (http://www.supportglobalhealth.org/) seeking support for global health spending through the United States Global Health Initiative. Many fear that even flat spending in this area could jeopardize important programs in vaccine research and treatment.

News like this highlights the important role that public-private partnerships play in supporting access to global health care. The Global Health Progress initiative seeks to bring research-based biopharmaceutical companies and global health leaders together to improve access to medicine and health care in the developing world. We are committed to being part of the effort to create a sustainable health care system that includes improving access to health care and continuing medical innovation and progress for all people.

Research-based biopharmaceutical companies and their partners around the world are working to implement sustainable solutions and strengthen the health care delivery systems so they can meet tomorrow’s challenges. Millions of people lack access to essential medicines due to factors including incomplete delivery systems, lack of training for health personnel, lack of infrastructure and the cost of treatments. We must address the underlying barriers to health care, such as weak and fragmented health systems, limited health care personnel and inadequate resources for scaling up proven solutions. The innovative research and development (R&D) of new drugs and vaccines is a critical component of improving health care and combating epidemics in developing countries.

Through meaningful public-private partnerships with others in the field, including policymakers in the developed and developing world, multi-lateral institutions, non-governmental organizations, and academia we can help shape sustainable solutions that improve the health of all people.

To stay informed on the latest news about global investment in pharmaceutical R&D and improving access to medicines, sign up to receive special alerts and newsletters. You can also spread the word about the efforts of the Global Health Progress initiative and keep others informed about how we’re affecting change around the world, or share your story about how you or someone you know is working to promote global health.

Via EPR Network
More Healthcare press releases

Business of Medicine, Doctors, Healthcare, Healthcare Products, Healthcare Professionals, Healthcare Services, Hospitals, Medical Apparel, Medicine, Nurses

White Collar Uniform Introduces our New Women’s Lab Coat Collection

Leave a comment

White Collar Uniform®, makers of the all new prestigious women’s lab coats is having their Grand Opening this month at our new exiting website online. White Collar Uniform’s clothing has been described as breakthrough clothing for men and women doctors and physicians in the medical field. White Collar clothing has been described by many medical professionals as being practical and having overwhelming beauty and style.

Our women and men lab coats are very upscale clothing for doctors and we have a very creative designing team working around the clock to make you look good. White Collar has invented the first every lab coat that can interact with the wearer by helping the doctor to hold their tools while in the consultation room and on the floor. This lab coat is spectacular says one doctor who happened to see our lab coats for the first time. We have created the best looking lab coat in the world and nobody can make claims against that!

White Collar Uniform’s top of the line lab coats can be purchased for under $50.00, which is more than a 45% savings from our standard price. White Collar Uniforms is the low price leader and we will not be undersold by anybody looking to take our place. Our top of the line lab coats are loaded with goodies that the doctors are going to really enjoy. Just take a look at our lab coats on any picture and you will see that we are the best looking coats out there – hands down!

Attention: There has been a lot of recent articles talking about lab coats and transmitting bacteria via through lab coats. Most doctors hang on to their lab coats for ages until they finally have to throw it away. We recommend that you change your lab coat every six months. There has been a lot of talk about soil proof coats and treated fabrics, “Don’t be too quick to get on this band-wagon!” Studies have show that these clothing can not be autoclaved so be careful about their labeling in general.

Don’t spend a lot of money on scrubs and lab coats that won’t hold up to the test of time. These so-called treated clothing’s are very expensive and they will probably send you running to the bank for cover. If it doesn’t say white collar, “Then it must be blue!” Save yourself a bundle and shop for White Collar Uniforms when you decide to purchase your next order of lab coats or scrubs online. Also you should watch out for repellant type materials which makes claims that doesn’t make sense most of the time.

White Collar Uniforms was founded several years ago by a well known inventor and medical provider in the medical field. He wanted to design a men’s lab coat for men and women that could let them use their hands more and be more practical at the same time. Since then, he has consulted hundreds and thousands of his constituents and his final works have been published amongst his peers and medical friends. Doctors deserve better and that’s why White Collar Uniforms invented its sporty designer lab coats.

Via EPR Network
More Healthcare press releases

Alternative medicine, Biotech, Business of Medicine, Drugs, Health 2.0, Healthcare, Healthcare Information, Healthcare Services, Healthcare Software, Healthcare Solutions, Online, Pharmaceuticals

Assay-Ready Chemistry Partnership between Molplex & Enamine

Leave a comment

Molplex and Enamine today announced a new partnership to offer the Enamine screening collection of 1.8 million stock chemicals through the Molplex online drug design and assay-ready chemical supply services. The agreement is a major step towards eliminating the high start-up costs ofdrug discovery, bringing sophisticated drug design, compound management and assay-ready chemistry to the world’s drug discovery scientists on demand.

The agreement adds Molplex online drug design systems to the deep experience in organic chemistry and compound management of Enamine to solve the problem of generating viable chemical leads for novel targets.

Molplex CEO David E. Leahy said: “We are very proud to be selected by Enamine as their partner for on demand drug discovery services at a time when major restructuring of the industry is creating new opportunities and new markets for our combined expertise. This agreement marks a step change in the size and scope of our assay-ready chemical supply service and major progress towards our goal of being the world’s first choice partner for enabling the long tail of drug discovery”

Via EPR Network
More Healthcare press releases

Alternative medicine, Anti-aging, Biotech, Business of Medicine, Diseases, Genetics, Health 2.0, Healthcare, Healthcare Information, Pharmaceuticals, Society

Gene Therapy and Stem Cell Therapy Standard Developed For A Unique Derivative Of Post Hetero-Plastic Inplantation Chronic Inflammation Syndrome, The NIDO Disease

Leave a comment

Researchers task force, led by faculties of T-Protocol, registered Genom Project as controlled genom project in the hosted database of NCBI, a publication matter authority and function assigned organization under oversee of Department of Health & Human Services, reached once to share the exegetical impression officially pre-published concerning the understanding specific spectrum of symptoms covering boroad range of character usually complained and observed through chronic inflammation, granuloma, some types of lymphoma and various uncommon symptoms to let physician scientists suspecting indicium of neurological diseases, NIDO disease, an unique type of post hetero-plastic implantation chronic inflammation syndrome and setting Massachusetts indications of treatments standardized manual (Massachusetts manual) & diagnostic and standardized medical treatment manual for post hetero-plastic inplantation chronic inflammation syndrome, specific edition against NIDO Disease.

The once defined causes of NIDO disease, an unique type of post hetero-plastic implantation chronic inflammation syndrome are considered each of a common living organism to cause conformational diseases like Creutzfeldt-Jakob disease, Alzheimer’s disease, Parkinson’s disease, Huntington’s disease and kinds of and a set of biochemical and physical reaction and response realized by cross-species gene- mutation, as biotransformation, easily describing natural physiological and biochemical changes in vivo substrate of human bodies. After this studies, standardized protocol of gene therapy and applied stem cell therapy is now in practice and on available.

Faculties,committing themselves entirely to the project, of each institutes and organizations participating the project to ascertain proteins and DNA/genomic DNA/genom of human, other mammal and virulent microorganism including bacillus/virus affecting each symptom and the symptoms’ spectrum expressed generally and observed commonly on patients suffered from NIDO disease, extraordinarily unique derived type of post hetero-plastic implantation chronic inflammation syndrome and to develop diagnostic standard and treatment protocol standardized and to find a clue compose gene therapy protocol and applied stem cell therapy protocol to entirely heal NIDO disease, an unique type of post hetero-plastic implantation chronic inflammation syndrome and to let all of current suffered patients from various combined symptoms directly derived by chronic inflammation and various tumors, have to express full surprise at the fact that these disease and patients suffered are made up and left no attention and no relief.

Via EPR Network
More Healthcare press releases

Biotech, Business of Medicine, Diseases, Drugs, Healthcare, Healthcare Information, Healthcare Professionals, Healthcare Solutions, Medicine, Online, Pharmaceuticals, Society

New UN Program Will Ensure Developing Nations Continue to Have Access to Drugs Effective At Treating Malaria

Leave a comment

Earlier this week, the United Nations announced a new plan of action designed to help fight disease resistance to artemisinin, the world’s most potent treatment for malaria. Launched by the UN World Health Organization (WHO) and the Roll Back Malaria Partnership (RBM), the groups hope to better contain and prevent resistance to artemisinins, the critical component of artemisinin-based combination therapies (ACTs), which are currently the most effective weapon in treating falciparum malaria.

The WHO’s announcement describes the plan as a five-step process which “aims to contain and prevent artemisinin resistance by stopping the spread of resistant parasites, increase monitoring and surveillance for artemisinin resistance, improve access to malaria diagnostic testing and rational treatment with ACTs, invest in artemisinin resistance-related research, and motivate action and mobilize resources.”

Global Health Progress is hopeful that this action plan will help to ensure that developing nations continue to have access to drugs that most effectively treat malaria. Many malaria-stricken countries lack the resources needed to keep an effective health care system running smoothly. Strong, effective health systems are vital to helping those in need of access to drugs, and health care improvements made today will strengthen the ability of countries to develop sustainable systems that can meet tomorrow’s challenges. Stopping the spread of drug-resistant strains of malaria and other diseases are essential to these goals.

Investing in local R&D capacity and national research systems is another way research-based biopharmaceutical companies help strengthen health systems. Local production can play a valuable role in building overall local capacity and enabling developing countries to increase access to essential medicines.

It is the responsibility of the entire international community to facilitate access to medicines. Success depends on all sectors working in partnership; not only to make medicines more accessible, but also to ensure continued innovation into new medicines for the treatment and prevention of all diseases.

About Global Health Progress:
Global Health Progress also supports efforts to raise awareness and mobilize resources to address health challenges in the developing world by bringing local leaders together with international health experts, policymakers, donor governments, and the private sector. www.globalhealthprogress.org;  twitter.com/globalhealth; facebook.com/pages/Global-Health-Progress/124850684219049;  linkedin.com/groups?home=&gid=2972068

Via EPR Network
More Healthcare press releases

Alternative medicine, Anti-aging, Biotech, Business of Medicine, Diseases, Genetics, Health 2.0, Healthcare, Healthcare Information, Pharmaceuticals, Society

Next Genetic Natural Stem Cell Therapy Established

Leave a comment

Division of Gene Medicine & Stem Cell Application, School of Medical Science, complete the research and established completely new protocol totally recovering natural bio mechanism of hair regrowth.

The researchers, led by Lord. Prof. Dr. Daichent Otto Rie, specified protein and genom to affect internal bio mechanism to generate hair and control the level of successful growth being low which is the baldness.

The key cast of the set of the bio cycle is hair follicles, which is stem cell on head skin and effect or holding function to cure many neurotic diseases and disorders like Alzheimer’s disease – Prion Disease and even Trion Disease (Post Hetero-Plastic Implantation Chronic Inflammation Syndrome; PhCIS) has absolutely unique character being retrieved absolute stem cell, which can recover the ability as stem cell after got adult. The key genom and DNA has been found through the Genom Project’s T-Protocol research developing in the government registered Genom Project since 2005. The most concentrated attention of researchers is not “what is cause” but “What protocol is best”.

The team of Prof.Daichent has successfully completed in vivo and in vivro experiment actually using voluntary patients whose types of hair loss being across over highly wide range extent to even lymphoma and cancer and finally established next genetic hair loss curing treatment protocol mainly composed of stem cell therapy and gene therapy.

Most of cases are treatable through entry level stem cell theraputic technique or HIV-1 Vector using high level technique but A20 introduction as gene therapy is required when treating patients being suffered from lymphoma, cancer or any neurotic diseases like Alzheimer’s disease – Prion Disease and even Trion Disease (Post Hetero-Plastic Implantation Chronic Inflammation Syndrome; PhCIS).

As Prof.Daichent points since 2005 being on School of Public Health of Harvard, in the treatment manual (published 2005), the key factor to overcome of lymphoma and chronic inflammation on human skin is extraordinary redundancy coding of polyglutamine DNA synthesis as the type of disease caused by pathological proteins and lack or heavy impairment of an specific DNA of A20.

Actually, the treatment protocol curing for baldness is also found through T-protocol which was essentially aimed at achieving causal and complete treatment of lymphoma, cancer, chronic inflammation and many neurotic diseases.

Via EPR Network
More Healthcare press releases

Business of Medicine, Drugs, Healthcare, Healthcare Information, Healthcare Professionals, Healthcare Services, Medicine, Therapies

ClinACE Initiates Global Clinical Research Awareness Day

Leave a comment

The world and the new millennium stands witness to revolutionary breakthroughs happening in the medical research arena. New drug or botanical discoveries and therapies that will perhaps cure life threatening diseases and bring about improved quality of life – is the order of the day.

All this and more, possible due to endless and tireless work in the area of Research and Development by organizations united on one single front. To meet unending medical demand and necessities and make effective healthcare more accessible to the population at large.

Research on humans to harness the goodness of potential drugs has been carried out since centuries. Human Trials are a definitive and most important link in the process of Discovery to Development and Commercialization. However, tales of unethical and almost inhuman conduct related to these trials with little or no protection of subject rights have been etched in history and in the minds of many.

The beginning of every change is awareness. A new idea, thought ingrained to bring about a difference is worthy of its cause. Human Trials since long have been a topic of prejudice and of concern to a few. Are they safe? Are they necessary? And many more such queries would always remain in ‘a valley of doubt’ if not answered or addressed accurately.

‘Global Clinical Research Awareness Day’ – An initiative by ClinACE to bring to light the ethical framework of Clinical Research which has undergone an evolution from negative perception, injustice, and manipulation of subject rights to bringing safe, effective and quality healthcare without compromise. It is our endeavor to spread the good word about Clinical Research and Protection of Subject Rights.

Via EPR Network
More Healthcare press releases

Biotech, Business of Medicine, Diseases, Drugs, Healthcare, Healthcare Information, Healthcare Professionals, Healthcare Solutions, Medicine, Online, Pharmaceuticals, Society

Global Health Progress Commends European Union and India Agreement Increasing Access to Drugs in Developing Countries

Leave a comment

According to a Reuter’s article, the European Union (EU) and India have come to an agreement which should ease the process of exporting Indian drug manufacturers’medicines to developing countries, increasing these countries’ access to drugs.

Karel De Gucht, commissioner of the European Union (EU) has confirmed an agreement between the EU and India that will resolve some of the disputes that lead to the seizure of generic drugs in transit last year. This agreement will allow shipments of medication to pass through Europe to developing nations without being checked for anything except counterfeiting.

The new agreement will also amend custom codes allowing shipments of medications from India to reach countries located in South America via Europe. The confirmation comes amid trade talks between the EU and India.

Global Health Progress commends the agreements between the European Union and India, which will increase access to drugs, primarily generic medication, for underdeveloped countries. This process affects the affordability of generic medications to underdeveloped countries which fight the prominence of infectious diseases such as HIV/AIDS and malaria.

Since the 1960s, the philanthropic efforts of research-based biopharmaceuticalcompanies have worked to get medicines to the people that need them the most. In 2005, biopharmaceutical companies responded to requests with more than $3 billion in medical products donated worldwide.

Via EPR Network
More Healthcare press releases

Business of Medicine, Health 2.0, Healthcare, Healthcare Information, Healthcare Services, Society

3D/4D Ultrasound The Best Bonding Experience Available With Your Unborn Baby By Setting Up Your Appointment With Adorable Baby 3D/4D Ultrasound!

Leave a comment

For a limited time, you can get a $10 discount just by mentioning this press release when you book your appointment.

When you first find out that you are pregnant, there are many things that will go through your mind. As your pregnancy continues and your unborn baby grows more and more, you will want to have the optimal bonding experiences with them.

This is especially something that the fathers are interested in. While the mothers can bond naturally by feeling the baby grow and kick in their wombs, fathers have this incredible chance to get a sneak peak at their baby before he or she is born.

Adorable Baby 3D/4D Ultrasound is the best place in Western California for you to get the best experience. Many people travel miles for the experience.

We are located at 411 Sycamore Valley Road West in Danville, California. We have different specials each month that will meet your needs. One of the best perks you will get by choosing us as your 3D/4D ultrasound provider is the fact that we offer a different approach to your typical hospital or doctor’s office setting. Our offices are private and comfortable, which is not something that you will usually get from your obstetricians office. Do you want more people to partake in your visit?

We have just the solution- our viewing room allows you to have up to five extra people to let in on your ultrasound.

Whether you want just a simple viewing to determine the gender of your baby, or you want to have ongoing visits to see your baby at different intervals of your pregnancy, we have just the package for you! Our packages start out at $75 and are very affordable no matter what your budget. You can even have your entire session set to a DVD so that you can cherish it for years to come. Your baby will look back on these videos in awe of the technology of being able to see footage before they were even born.

If you have any questions about what we offer, or our facilities, do not hesitate to contact our offices and consult with one of our professionals. One of the most common questions that we get from soon to be parents is if the procedure is safe. We can assure you that we follow strict guidelines and will offer you the safest 3D/4D ultrasound around.

Adorable Baby 3D/4D Ultrasound has been dedicated to serving parents-to-be for quite some time and would love to help you make incredible memories of your little one. Just remember, mention this press release to get $10 off of the price of your package. There has never been a better time.

Via EPR Network
More Healthcare press releases

Biotech, Business of Medicine, Diseases, Drugs, Healthcare, Healthcare Information, Healthcare Professionals, Healthcare Solutions, Medicine, Online, Pharmaceuticals, Society

Global Health Progress Applauds HIV-Prevention Medicine Trial, Encourages Access to Medicines in Developing Countries

Leave a comment

The New England Journal of Medicine recently released the results of a ground-breaking trial of an HIV-prevention method called oral pre-exposure prophylaxis (PrEP). Data from the trial revealed an almost 44 percent reduction of new HIV infections among participants who took the antiretroviral tablet daily to prevent HIV, compared to those who took the placebo pill.

Participants in the study included 2,499 HIV-negative gay men, transgender women, and other men who have sex with men (MSM) from Peru, Ecuador, Brazil, South Africa, Thailand and the United States; these were randomly chosen to receive the antiretroviral (ARV) drug TDF/FTC (brand name Truvada) or a placebo pill. Regular HIV tests were administrated throughout the study. At the end of the trial, 36 participants who took Truvada had become infected, compared to 64 of the participants who took the placebo pill.

Similar trials are currently being conducted among heterosexuals in Africa and injection drug users in Thailand. Additionally, a trial of a similar ARV in gel form is currently being tested in three US cities, Pittsburgh, Boston and Birmingham, Alabama.

Global Health Progress is encouraged by the outcome of this trial, as it could lead to the prevention of HIV in developing countries and around the world. However, additional funding is needed not only to continue developing drugs like this, but to increase access to medicines around the world. As the world of medicine continues to advance, it is the responsibility of the entire international community to facilitate access to medicines. Success depends on all sectors working in partnership; not only to make medicines more accessible, but also to ensure continued innovation into new medicines for the treatment and prevention of all diseases.

Research-based biopharmaceutical companies help the fight against the HIV/AIDS epidemic by providing millions of doses of anti-retroviral drugs at discounted prices and, in some cases, for free to patients in developing countries. These donation programs for Least Developed Countries and sub-Saharan Africa, together with programs for lower and middle income countries, apply to more than 87 percent of all people living with HIV/AIDS worldwide.

About Global Health Progress:
Global Health Progress also supports efforts to raise awareness and mobilize resources to address health challenges in the developing world by bringing local leaders together with international health experts, policymakers, donor governments, and the private sector. www.globalhealthprogress.org; twitter.com/globalhealth;facebook.com/pages/Global-Health-Progress/124850684219049; linkedin.com/groups?home=&gid=2972068

Via EPR Network
More Healthcare press releases

Alternative medicine, Biotech, Business of Medicine, Drugs, Health 2.0, Healthcare, Healthcare Information, Healthcare Services, Healthcare Software, Healthcare Solutions, Online, Pharmaceuticals

Molplex Launches Novel ‘Drug Discovery On Demand’ Service

Leave a comment

An innovative new online “drug discovery on demand” platform has been launched by Molplex, a company specializing in products and services for the life sciences. Designed to help drug discovery groups working anywhere in the world, it aims to eliminate the high start-up costs and minimize the financial risks traditionally associated with inventing new medicines.

Molplex CEO David Leahy said: “As the pharmaceutical industry changes, a new ecosystem of small, flexible teams operating as “Micro Pharmas” is emerging. Molplex will provide the services they need to succeed at inventing better medicines at lower cost”.

The first version of the new Molplex system launched today offers free access to sophisticated drug design systems, high quality assay-ready stock chemicals and high content biological screening at www.molplex.com.

Via EPR Network
More Healthcare press releases